OXBRYTA (Voxelotor)

**Product type:** Human Prescription Drug

**Active ingredient:** VOXELOTOR

**Strength:** 300 mg/1

**Dosage form:** Tablet, For Suspension

**Route:** Oral

**Labeler:** Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.

**Marketing category:** NDA (NDA216157)

**Pharmacologic class:** Cytochrome P450 3A4 Inhibitors [MoA], Hemoglobin S Polymerization Inhibitor [EPC], Hemoglobin S Polymerization Inhibitors [MoA]